[Skip to Content]
[Skip to Content Landing]
March 15, 1995

Gynecologic Oncologists Optimistic About Diagnosis, Therapy Gains From Reported Research

JAMA. 1995;273(11):836-837. doi:10.1001/jama.1995.03520350018007

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.


USING RETINOIC acid to boost the efficacy of chemotherapy, laparoscopic staging of ovarian cancer, a potential prognostic test for cervical cancer patients, and the ability of the controversial abortifacient mifepristone (also known as RU486) to inhibit ovarian cancer cell division were among the research topics recently presented at the 26th annual meeting of the Society of Gynecologic Oncologists in San Francisco, Calif.

While most of the reported work involved in vitro studies or preliminary clinical trials, the researchers are optimistic that their approaches may yield substantial advances in the diagnosis and treatment of gynecologic cancers.

For example, one of the in vitro studies suggests that retinoic acid may greatly increase the efficacy of cisplatin and paclitaxel (Taxol, Bristol-Myers Squibb, Princeton, NJ) against some types of ovarian cancers. Researchers at the University of Louisville (Ky) School of Medicine added retinoic acid to three common ovarian cell line cultures, OVCAR-3, UL-1, and

First Page Preview View Large
First page PDF preview
First page PDF preview